Optimal therapy in genotype 4 chronic hepatitis C: finally cured?

被引：27

作者：

Abdel-Razek, Wael ^{[1
]}

Waked, Imam ^{[1
]}

机构：

[1] Menoufiya Univ, Natl Liver Inst, Hepatol Dept, Menoufia, Egypt

来源：

LIVER INTERNATIONAL | 2015年 / 35卷

关键词：

direct acting antivirals; genotype; 4; hepatitis C; interferon-free regimens; SUSTAINED VIROLOGICAL RESPONSE; PLUS RIBAVIRIN TREATMENT; CHRONIC HCV; INTERFERON-FREE; TREATMENT-NAIVE; SOFOSBUVIR PLUS; VIRUS-INFECTION; COMBINATION; EPIDEMIOLOGY; LEDIPASVIR;

D O I：

10.1111/liv.12724

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Optimal therapy for patients with hepatitis C virus (HCV) genotype 4 (HCV-4) infection is changing rapidly, and the possibility of a total cure is near. The standard of care has been combination pegylated interferon (PEG-IFN)-ribavirin (RBV), with modest response rates and considerable adverse events. Since the introduction of sofosbuvir (SOF), simeprevir (SIM), and daclatasvir (DCV), the duration of treatment has been significantly shortened and response rates have increased. The recommended treatment for IFN-eligible patients is PEG-IFN/RBV plus SOF, SIM or DCV. In IFN ineligible patients, the optimal regimen is a 24-week course of SOF/RBV, or a 12-week course of SOF-SIM or SOF-DCV with or without RBV. The pipeline for patients with chronic HCV is highly active. IFN-free combinations with paritaprevir-ombitasvir, SOF-ledipasvir, or DCV-asunaprevir (ASV)-beclabuvir (BMS-791325) for 12weeks or less with close to 100% cure rates will soon become the optimal therapy.

引用

页码：27 / 34

页数：8

共 48 条

[1]

AASLD and IDSA, REC TEST MAN TREAT H

[2] SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY [J].

Afdhal, N. ;

Everson, G. ;

Calleja, J. L. ;

McCaughan, G. ;

Symonds, W. T. ;

Denning, J. ;

McNair, L. ;

McHutchison, J. G. ;

Arterburn, S. ;

Charlton, M. ;

Reddy, R. ;

Asselah, T. ;

Gane, E. ;

Forns, X. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S28-S28

[3] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Zeuzem, Stefan ;

Kwo, Paul ;

Chojkier, Mario ;

Gitlin, Norman ;

Puoti, Massimo ;

Romero-Gomez, Manuel ;

Zarski, Jean-Pierre ;

Agarwal, Kosh ;

Buggisch, Peter ;

Foster, Graham R. ;

Braeu, Norbert ;

Buti, Maria ;

Jacobson, Ira M. ;

Subramanian, G. Mani ;

Ding, Xiao ;

Mo, Hongmei ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Mangia, Alessandra ;

Marcellin, Patrick .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898

[4] IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C [J].

Asselah, Tarik ;

De Muynck, Simon ;

Broet, Philippe ;

Masliah-Planchon, Julien ;

Blanluet, Maud ;

Bieche, Ivan ;

Lapalus, Martine ;

Martinot-Peignoux, Michelle ;

Lada, Olivier ;

Estrabaud, Emilie ;

Zhang, Qian ;

El Ray, Ahmed ;

Vidaud, Dominique ;

Ripault, Marie-Pierre ;

Boyer, Nathalie ;

Bedossa, Pierre ;

Valla, Dominique ;

Vidaud, Michel ;

Marcellin, Patrick .

JOURNAL OF HEPATOLOGY, 2012, 56 (03) :527-532

[5] Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 [J].

De Nicola, Stella ;

Aghemo, Alessio ;

Rumi, Maria Grazia ;

Galmozzi, Enrico ;

Valenti, Luca ;

Soffredini, Roberta ;

De Francesco, Raffaele ;

Prati, Gian Maria ;

D'Ambrosio, Roberta ;

Cheroni, Cristina ;

Donato, Maria Francesca ;

Colombo, Massimo .

HEPATOLOGY, 2012, 55 (02) :336-342

[6]

Doss W, EGYPTIAN NATL CONTRO

[7] Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues [J].

Esmat, Gamal ;

El Kassas, Mohamed ;

Hassany, Mohamed ;

Gamil, Mohamed ;

El Raziky, Maissa .

LIVER INTERNATIONAL, 2014, 34 :24-28

[8]

Esmat GE, 2014, SOFOSBUVIR PLUS RIBA

[9] The changing epidemiology of hepatitis C virus infection in Europe [J].

Esteban, Juan I. ;

Sauleda, Silvia ;

Quer, Josep .

JOURNAL OF HEPATOLOGY, 2008, 48 (01) :148-162

[10] SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1-6 HCV INFECTION [J].

Everson, G. T. ;

Tran, T. T. ;

Towner, W. J. ;

Davis, M. N. ;

Wyles, D. ;

Nahass, R. ;

McNally, J. ;

Brainard, D. M. ;

Han, L. ;

Doehle, B. ;

Mogalian, E. ;

Symonds, W. T. ;

McHutchison, J. G. ;

Morgan, T. ;

Chung, R. T. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S46-S46

← 1 2 3 4 5 →